BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2537348)

  • 21. Topical mechlorethamine therapy for mycosis fungoides.
    Price NM; Constantine VS; Hoppe RT; Fuks ZY; Farber EM
    Br J Dermatol; 1977 Nov; 97(5):547-50. PubMed ID: 588466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel.
    Benjamin Chase A; Markel K; Tawa MC
    Clin J Oncol Nurs; 2015 Dec; 19(6):E131-9. PubMed ID: 26583648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
    Querfeld C; Geskin LJ; Kim EJ; Scarisbrick JJ; Quaglino P; Papadavid E; Angello JT; Ortiz-Romero PL
    J Invest Dermatol; 2021 Jun; 141(6):1601-1604.e2. PubMed ID: 33347924
    [No Abstract]   [Full Text] [Related]  

  • 24. Topical nitrogen mustard in mycosis fungoides.
    Zachariae H
    Int J Clin Pharmacol Res; 1985; 5(3):193-8. PubMed ID: 4018954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topical chemotherapy in mycosis fungoides.
    Grupper C; Durepaire R
    Bull Cancer; 1977; 64(2):323-34. PubMed ID: 912134
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
    Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
    Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of mycosis fungoides: total-skin electron-beam irradiation vs topical mechlorethamine therapy.
    Hamminga B; Noordijk EM; van Vloten WA
    Arch Dermatol; 1982 Mar; 118(3):150-3. PubMed ID: 7065660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term topical nitrogen mustard treatment does not induce pulmonary fibrosis in MF patients.
    Nielsen M; Rasmussen K; Knudsen N; Thestrup-Pedersen K
    Acta Derm Venereol; 1994 Jan; 74(1):70-1. PubMed ID: 7908491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
    Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
    Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In brief: mechlorethamine gel (Valchlor) for cutaneous T-Cell lymphoma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66. PubMed ID: 25988964
    [No Abstract]   [Full Text] [Related]  

  • 31. Cutaneous T-cell lymphoma: clinicopathological relationships, therapy and survival in ninety-two patients.
    Hamminga L; Hermans J; Noordijk EM; Meijer CJ; Scheffer E; Van Vloten WA
    Br J Dermatol; 1982 Aug; 107(2):145-55. PubMed ID: 6809030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.
    Kim EJ; Geskin L; Guitart J; Querfeld C; Girardi M; Musiek A; Mink DR; Williams MJ; Angello JT; Bailey WL
    J Am Acad Dermatol; 2020 Sep; 83(3):928-930. PubMed ID: 32089294
    [No Abstract]   [Full Text] [Related]  

  • 33. Commentary and update: topical chemotherapy with mechlorethamine for mycosis fungoides.
    Vonderheid EC; Van Scott EJ
    Cleve Clin Q; 1983; 50(2):97-100. PubMed ID: 6640944
    [No Abstract]   [Full Text] [Related]  

  • 34. Topical treatment of early cutaneous T-cell lymphoma.
    Ramsay DL; Meller JA; Zackheim HS
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy.
    Vonderheid EC; Van Scott EJ; Wallner PE; Johnson WC
    Cancer Treat Rep; 1979 Apr; 63(4):681-9. PubMed ID: 109206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical mechlorethamine chemotherapy. Considerations on its use in mycosis fungoides.
    Vonderheid EC
    Int J Dermatol; 1984 Apr; 23(3):180-6. PubMed ID: 6373639
    [No Abstract]   [Full Text] [Related]  

  • 37. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
    Dolan ME; McRae BL; Ferries-Rowe E; Belanich M; van Seventer GA; Guitart J; Pezen D; Kuzel TM; Yarosh DB
    Clin Cancer Res; 1999 Aug; 5(8):2059-64. PubMed ID: 10473086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focal contact sensitivity to nitrogen mustard in lesions of cutaneous T-cell lymphoma (mycosis fungoides).
    Shelley WB
    Acta Derm Venereol; 1981; 61(2):161-4. PubMed ID: 6165197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
    Nguyen CV; Bohjanen KA
    Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycosis fungoides in a lung transplant recipient with advanced ciclosporin nephropathy: management with mechlorethamine and subsequent renal transplantation.
    Laffitte E; Venetz JP; Aubert JD; Duchosal MA; Panizzon RG; Pascual M
    Dermatology; 2008; 217(1):87-8. PubMed ID: 18446031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.